Immunoassay system utilizing antibody-coated magnetic particles and glycan-recognizing receptors to detect cancer-specific biomarkers in serum samples. Compatible with standard ELISA equipment and automated diagnostic platforms.
Manufactured by
Glycanostics, s.r.o.
Bratislava, Slovakia
At Glycanostics, our aim is to develop, clinically validate register an affordable, non-invasive next-gen liquid biopsy prostate cancer diagnostic test with accuracy of up to 90%.